rgb

5
2 2 3 3 4 4 5 5 7 7 8 8 9 9 10 10 11 11 12 12 1 2 R G B 1 157 144 160 2 81 170 230 3 104 160 210 4 25 76 128 5 15 86 163 6 52 71 120 7 29 96 163 8 24 84 144 9 10 1 0 2 4 6 8 10 12 14 Chart Row 5 Row 6 Ro Row 10 Row 11 Ro

Upload: goel-vaibhav

Post on 04-Dec-2015

218 views

Category:

Documents


0 download

DESCRIPTION

rgb

TRANSCRIPT

Page 1: RGB

2 23 34 45 57 78 89 9

10 1011 1112 12

12

R G B1 157 144 1602 81 170 2303 104 160 2104 25 76 1285 15 86 1636 52 71 1207 29 96 1638 24 84 1449

10

1 20

2

4

6

8

10

12

14

Chart Title

Row 5 Row 6 Row 7 Row 8 Row 9Row 10 Row 11 Row 12 Row 13 Row 14

Page 2: RGB

1 20

2

4

6

8

10

12

14

Chart Title

Row 5 Row 6 Row 7 Row 8 Row 9Row 10 Row 11 Row 12 Row 13 Row 14

Page 3: RGB

0%

20%

40%

60%

80%

100%

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000~ 90 USD bn *

Amgen has its major focus on Adjuvants with 55% of contribution.

Roche is the largest contributor among all the companies with the Top 3 oncology drugs like Avastin, Herceptin & Rituxan.

Novartis is at the Second position in both Adjuvants and Oncology group.

Celgene is oncology focused company having all small molecule drugs in its portfolio.Revlimid is Largest among small molecule

KHK is the only Japanese company among top 5 contributors and it deals with Amgen’s Adjuvant drugs for Japanese Market

Merck & Co major contribution in Adjuvant is indicated by a single drug i.e. Emend

Pfizer being a Diversified company holds position in top 10 Oncology Market

Major three contributors of others areGSK, Bayer, Astellas

Major three contributors of others areInsys Therapeutics, Otsuka, Spectrum

Tota

l Onc

olog

y M

arke

t 201

4

Amgen

Novartis

Roche

Novartis

Celgene

JNJ

JNJ

KHK

BMS

Roche

Elli LillyAstraZeneca

PfizerTakeda

Merck & CoOthers

Core

O

ncol

ogy

Adju

vantMerck & CoSanofiEisaiGSKTevaOthers

Page 4: RGB

0%

20%

40%

60%

80%

100%

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000~ 90 USD bn *

Amgen has its major focus on Adjuvants with 55% of contribution.

Roche is the largest contributor among all the companies with the Top 3 oncology drugs like Avastin, Herceptin & Rituxan.

Novartis is at the Second position in both Adjuvants and Oncology group.

Celgene is oncology focused company having all small molecule drugs in its portfolio.Revlimid is Largest among small molecule

KHK is the only Japanese company among top 5 contributors and it deals with Amgen’s Adjuvant drugs for Japanese Market

Merck & Co major contribution in Adjuvant is indicated by a single drug i.e. Emend

Pfizer being a Diversified company holds position in top 10 Oncology Market

Major three contributors of others areGSK, Bayer, Astellas

Major three contributors of others areInsys Therapeutics, Otsuka, Spectrum

Tota

l Onc

olog

y M

arke

t 201

4

Amgen

Novartis

Roche

Novartis

Celgene

JNJ

JNJ

KHK

BMS

Roche

Elli LillyAstraZeneca

PfizerTakeda

Merck & CoOthers

Core

O

ncol

ogy

Adju

vantMerck & CoSanofiEisaiGSKTevaOthers